MSR21 Cost-Effectiveness Analysis of Treatments for Nonsense Mutation Duchenne Muscular Dystrophy: Expert Validation of Model Face Validity
نویسندگان
چکیده
To assess the face validity of a decision-analytic model evaluating cost-utility ataluren for treatment nonsense mutation Duchenne muscular dystrophy (nmDMD). This was Delphi panel comprising physicians with first-hand experience nmDMD. Consensus investigated key parameters, including expected benefit early treatment, mortality, informal caregiving, and patient health status quality life (assessed using Health Utility Index [HUI]) four disease stages: (1) ambulatory (patient age: 10 years), (2) non-ambulatory, not yet requiring ventilation support, (3) at time initiation night-time (4) full-time support. Nine experts from five countries participated in study. obtained all questions after three rounds (except two HUI-questions concerning hand function [dexterity]). Panelists agreed that starting 2 vs. 5 years age would be to delay loss ambulation by an additional years, support 3 respectively. On average, 4%, 13%, 33% patients reaching stages (1), (2), were die these stages, expectancy stage years. All panelists caregivers provided day-to-day care/support nmDMD across stages. HUI-derived utilities 1.0000 on top best supportive care (BSC) 0.7337 BSC alone. Corresponding estimates 0.3179 0.2672, 0.1643 0.0913, -0.0732 -0.1163. study confirms cost-effectiveness provides further evidence benefits ataluren.
منابع مشابه
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
BACKGROUND Several treatments are on the horizon for Duchenne muscular dystrophy (DMD), a terminal orphan disease. In many jurisdictions, decisions regarding pricing and reimbursement of these health technologies comprise evidence of value for money. OBJECTIVE The objective of this study was to develop a cost-effectiveness model based on the Duchenne muscular dystrophy Functional Ability Self...
متن کاملMutation rate in Duchenne muscular dystrophy.
The estimation of mutation rates in our own species has emerged as an integral part of human genetic research. Prerequisites for existing methods of calculating mutation rates are the total birth statistics and/or frequency of patients in the whole population. Unfortunately, no such records are being maintained adequately in India; a fact which was painfully realized by Haldane (1965). It is fo...
متن کاملPhase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
BACKGROUND Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dystrophin gene, resulting in a premature stop codon in the corresponding mRNA and failure to generate a functional protein. Ataluren (PTC124) enables ribosomal readthrough of premature stop codons, leading to production of full-length, functional proteins. METHODS This Phase 2a open-la...
متن کاملDuchenne muscular dystrophy An overview of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) affects approximately 1 in 3,500 live male births [1]. It is caused by a large variety of mutations in the dystrophin gene. Because of these mutations, the body can no longer make dystrophin which is a protein important for stabilisation of the muscle cell during a contraction. Without dystrophin, muscle cells are damaged and slowly replaced by fat and scar tis...
متن کاملP164: Adeno-Associated Viral Vectors in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (BMD) is an inherited X-link disease. The incidence of this muscle-wasting disease is 1:5000 male live births. Mutation in the gene coding for dystrophin is the main cause of BMD. Most cases of this disease succumb to respiratory and cardiac failure in 3rd to 4th decades. The slow progression of BMD and recent achievement of gene therapies make it as an appropriate c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2022
ISSN: ['1098-3015', '1524-4733']
DOI: https://doi.org/10.1016/j.jval.2022.04.1228